Wegovy pill introduction in the U.S. may serve as the turning point that transforms a beleaguered GLP‑1 leader into a viable 2x

Danish obesity drugmaker Novo Nordisk's head of public affairs in the U.S. has left the company, according to an internal memo seen by Reuters, at a time when the firm is battling to revive its fortunes in its top market.

Novo’s oral Wegovy launch has intensified competition for Eli Lilly heading into 2026. ・Lilly’s outlook hinges on oral drug approvals, data readouts and execution this year. ・Eli Lilly’s share weakness reflects pricing pressure amid the GLP-1 rivalry.

The patent in question is due to lapse in March next year. The court is scheduled to take up Natco's challenge for further hearing in February

"As such, it is a modest positive, suggesting Nvidia remains on track, broadly in line with or slightly ahead of expectations, rather than a moment that fundamentally changes the investment case." Shares in Danish pharmaceuticals firm Novo Nordisk (NOVO-B.